Skip to content

Study on "Minvitein" - A nutritional powdered supplement for adults for everyday nutrition with Minerals and Vitamins

An Open Label, Prospective, Non-Randomised, Non-Comparative, Single Arm Clinical Study to Evaluate the Effectiveness, Safety and Tolerability of “Minvitein ? of Essen Fooddies India Pvt. Ltd. as a Nutritional Supplement in Adult Subjects

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/07/043935
Enrollment
50
Registered
2022-07-12
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Minvitein: Route of Administration : Oral Formulation : Powered Nutritional Formulation Dose : 50g (5 scoops) in 150ml lukewarm water Dosage : OD for 3 months Control Intervention1: No

Sponsors

Essen Fooddies India Pvt Ltd
Lead Sponsor
Aurous HealthCare Research and Development India Private Limited
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. Clinically healthy adult subjects between the ages of 18 and 65 years (both ages and all genders inclusive). 2. Subjects who are willing to abstain from use of herbal, allopathic or other nutritional supplements that are indicated at improving general health. 3. Subjects who are not on rapid weight loss programs such as but not limited to keto, paleo, warrior, caveman diets. Intermittent fasting is permitted. 4. Subjects who have scored 12-14 in Mini Nutritional Assessment MNA-SF Questionnaire at the time of screening. 5. Subjects who are willing to give informed consent for participation, able to comprehend and understand the responsibilities during screening and treatment period. 6. Subjects who are willing not to participate in any other clinical trial during participation in the current trial.

Exclusion criteria

Exclusion criteria: 1. Subjects with known hypersensitivity to the ingredients of the investigational product. 2. Subjects who are diagnosed with Galactosemia. 3. Subjects who have an active infection, disease or disorder that will prevent them from fully satisfying the responsibilities of the study. 4. Subjects with history of seizures, uncontrolled diabetes, hypertension or major cardiac illness like congestive heart failure etc. 5. Subjects on remission from cancer of any type less than 5 years at the time of screening. 6. Subjects who are planning a pregnancy and/or currently breastfeeding. 7. Subjects who have participated in a clinical study less than 1 month before screening. 8. Any significant medical condition (e.g., significant psychiatric or neurological disorders , active alcohol/drug abuse, etc.), any medical condition that is unstable/poorly controlled or other factor (e.g., planned relocation) that the Investigator felt would interfere with study evaluations and study participation. 9. Subjects who are mentally unable to comprehend the responsibilities and adhere to the stipulations of the protocol. 10. Subjects, who in the opinion of the Investigator are not eligible for enrolment in the study.

Design outcomes

Primary

MeasureTime frame
1. Strength : Stair Climbing : Increase of 20% from baseline 2. Controls Hunger : Daily EATS Questionnaire : Decrease of 10 total score 3. Satiety : Daily EATS Questionnaire : Increase of 2 scores from baseline 4. Patient’s Global Impression Scale : Score of 4 at end of study. Timepoint: 1. Strength : Stair Climbing : Day 1, Day 45, Day 90 2. Controls Hunger : Daily EATS Questionnaire : Day 1, Day 45, Day 90 3. Satiety : Daily EATS Questionnaire : Day 1, Day 45, Day 90 4. Patient’s Global Impression Scale : Day 90

Secondary

MeasureTime frame
NoneTimepoint: None

Countries

India

Contacts

Public ContactDr VT Sriraam

Aurous HealthCare R&D India Pvt. Ltd.

md@auroushealthcare.com9840909155

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026